IgA nephropathy: an interesting autoimmune kidney disease
A Rajasekaran, BA Julian, DV Rizk - The American journal of the medical …, 2021 - Elsevier
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis
worldwide. It is a leading cause of chronic kidney disease and progresses to end-stage …
worldwide. It is a leading cause of chronic kidney disease and progresses to end-stage …
Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial
Importance The effect of glucocorticoids on major kidney outcomes and adverse events in
IgA nephropathy has been uncertain. Objective To evaluate the efficacy and adverse effects …
IgA nephropathy has been uncertain. Objective To evaluate the efficacy and adverse effects …
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …
Therapeutic targeting of the complement system: from rare diseases to pandemics
P Garred, AJ Tenner, TE Mollnes, FO Levy - Pharmacological reviews, 2021 - Elsevier
The complement system was discovered at the end of the 19th century as a heat-labile
plasma component that “complemented” the antibodies in killing microbes, hence the name …
plasma component that “complemented” the antibodies in killing microbes, hence the name …
[HTML][HTML] Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of …
J Barratt, R Lafayette, J Kristensen, A Stone… - Kidney international, 2023 - Elsevier
The therapeutic potential of a novel, targeted-release formulation of oral budesonide
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …
(Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase …
Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides
JC Jennette - Clinical and experimental nephrology, 2013 - Springer
The nomenclature and classification of vasculitis has been difficult and controversial for
many decades. This is problematic both for research on vasculitis as well as clinical care of …
many decades. This is problematic both for research on vasculitis as well as clinical care of …
Current treatment of IgA nephropathy
IgA nephropathy (IgAN) is the most common type of glomerulonephritis in Asia and the
Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and …
Western world. In most patients, it follows an asymptomatic to oligosymptomatic course and …
The mucosal immune system and IgA nephropathy
L Gesualdo, V Di Leo, R Coppo - Seminars in immunopathology, 2021 - Springer
The precise pathogenesis of immunoglobulin A nephropathy (IgAN) is still not clearly
established but emerging evidence confirms a pivotal role for mucosal immunity. This review …
established but emerging evidence confirms a pivotal role for mucosal immunity. This review …
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Background IgA nephropathy is thought to be associated with mucosal immune system
dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage …
dysfunction, which manifests as renal IgA deposition that leads to impairment and end-stage …